Pharmaceutical drug

Should the government ban experiments on animals in the pharmaceutical industry ? This is probably one of the most controversial topics currently in the science, as well as in the government. It’s really an important question because nowadays, more and more experiments are made on animals, and medicine is in progress. Of course research is important but it should not be carried out at any costs. In this case, it's really hard to have a clear-cut opinion (either those who want medecine to progress

Nanomedicine • A Brief History of Nanomedicine • Theranostics • Targeted Drug-Delivery • Polymer Therapeutics • Regenerative Medicine • Ethical and societal issues The aim of this briefing paper is to provide concise, correct and balanced information to advance public debate among consumers, media, policy makers, producers and researchers as part of the European Commission-funded Nanobio-RAISE project.1 It results from the combined contributions of natural and social scientists

Negociates price, Formulary third party administrator of prescription drug programs Main objectives: Resolve the dilemma of the increase of health care cost Chronic diseases 96% of drug costs 75% of medical costs Treat with drug Review management of chronic disease Advanced pharmacy®: Reducing costs by improving quality Patient’s service: Medco Health Store™: mail order Reduce cost of drug Extend access of drug Better compliance http://www.medcohealth.com Advanced pharmacy®:

ones are still sold to big pharmaceutical companies because those little companies are very competitive and flexible relating to a quick time of launching new products on the market. - The other dominant business model is that of the large, vertically integrated company. These large firms have integrated everything inside the boundaries of the firm, from research and development (R&D) to production to marketing and after sales monitoring. The ones in pharmaceuticals have competed through finding

Approche documentaire : dédoublement d’un mélange racémique. En 1992, la Food and Drug Administration encourage la commercialisation de principes actifs sous forme d’énantiomères purs : pourquoi est-il nécessaire de séparer deux énantiomères d’un mélange racémique ? Comment procéder ? Niveau : PCSI- premier semestre Activité réalisable par les étudiants en autonomie. Discussion possible en classe. Thèmes : le thème abordé dans cette activité est celui de la chimie organique, plus précisément

Banks Food producers Oil & gas producers Household goods & home construction Pharmaceuticals & biotechnology Banks Banks Oil & gas producers Oil & gas producers Banks Software & computer services Industrial metals & mining Banks Fixed line telecommunications Oil & gas producers Banks Technology hardware & equipment Pharmaceuticals & biotechnology Pharmaceuticals & biotechnology Software & computer services Pharmaceuticals & biotechnology Automobiles & parts Market value $m 329,259.7 316,230.8 256

industrial sectors are now dealing with the issue of counterfeit. Here’s a non exhaustive list of goods that are subject to intellectual property rights infringements: car parts, apparel, footwear, designers’ clothes, chemicals, consumers’ electronic, pharmaceuticals, food, drink, agricultural products, personal accessories (jewels, watches,…), tobacco and alcohol, toys, sanitary products,… • Digital piracy remains the most known aspect of counterfeit in globalization. Thanks to the Internet and various

Stratégie UCB has a clear long-term strategy to realise its vision. Since 2004, when the company was a diversified pharmaceuticals, chemicals and films conglomerate, we have successfully delivered the first three stages of this five-step strategy and are now poised to enter the ‘growth’ phase.. Transformation (completed in 2005) The transformation of UCB into a biopharmaceutical company with a development portfolio of small- and large-molecule drugs was achieved through the acquisition in 2004

 « Last week pharmaceutical drug sales topped $600 billion. The number one best seller was Lipitor, a stin drug for lowering cholesterol. It brought in $12.9 billion. Next is Plavix, for thinning the blood ($5.9 million), closely followed by Zocor, the worlds’s first over the counter statin ($5.3 billion). Next is Norvasc, for high blood pressure ($5 billion). So that’s almost $24 billion dollars for the top four cardiovascular drugs. The natural alternatives for this pharmaceutical goldmine are

MIS - data modeling : drug expenditure survey The survey team wanted to determine which drugs and dosages were being used for various operations, to ensure that correct clinical decisions were being made and that patients and taxpayers were not paying for unnecessary (or unnecessarily expensive) drugs. Each hospital in the survey was given a unique hospital number to distinguish it from other hospitals (in some cases two hospitals had the same name). All hospital numbers were prefixed H (for hospital)